actabiomedicaActa Biomedica ScientificaActa Biomedica Scientifica2541-94202587-9596Scientific Centre for Family Health and Human Reproduction Problems10.29413/ABS.2024-9.3.10actabiomedica-4820Research ArticleИНФЕКЦИОННЫЕ БОЛЕЗНИINFECTIOUS DISEASESЛекарственный мониторинг антиретровирусных препаратов у детей с перинатальной ВИЧ-инфекциейDrug monitoring of antiretroviral drugs in children with perinatal HIV infectionhttps://orcid.org/0000-0001-5790-6282СамбяловаА. Ю.SambyalovaA. Yu.

Самбялова Александра Юрьевна – младший научный сотрудник лаборатории персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Alexandra Yu. Sambyalova – Junior Research Officer at the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

sambialova95@mail.ruhttps://orcid.org/0000-0003-3704-830XБаироваТ. А.BairovaT. A.

Баирова Татьяна Ананьевна – доктор медицинских наук, заведующая лабораторией персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Tatyana A. Bairova – Dr. Sc. (Med.), Head of the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

tbairova38@mail.ruhttps://orcid.org/0000-0003-3678-7274БельскихА. В.BelskikhA. V.

Бельских Алексей Владимирович – кандидат химических наук, инженер лаборатории персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Aleksey V. Belskikh – Cand. Sc. (Chem.), Engineer at the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

alex590750@yandex.ruhttps://orcid.org/0000-0001-9201-7288МанаенковаТ. Л.ManaenkovaT. L.

Манаенкова Татьяна Леонидовна – аспирант, ФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»; инфекционист

664003, г. Иркутск, ул. Тимирязева, 16

664035, г. Иркутск, ул. Cпартаковская, 11

Tatiana L. Manaenkova – Postgraduate, Scientific Сentre for Family Health and Human Reproduction Problems; Infectious Disease Specialist

Timiryazeva str. 16, Irkutsk 664003

Spartakovskaya str. 11, Irkutsk 664035

vodnay.stihiay@gmail.comhttps://orcid.org/0000-0001-6050-5287БеляеваЕ. В.BelyaevaE. V.

Беляева Елена Владимировна – кандидат биологических наук, научный сотрудник лаборатории персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Elena V. Belyaeva – Cand. Sc. (Biol.), Research Officer at the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

belyeva_irk@mail.ruhttps://orcid.org/0000-0003-0690-4636ЕршоваО. А.ErshovaO. A.

Ершова Оксана Александровна – кандидат биологических наук, научный сотрудник лаборатории персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Oksana A. Ershova – Cand. Sc. (Biol.), Research Officer at the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

oksana111088@mail.ruhttps://orcid.org/0000-0002-9720-8750НемчиноваН. В.NemchinovaN. V.

Немчинова Надежда Владимировна – лаборант-исследователь лаборатории персонализированной медицины

664003, г. Иркутск, ул. Тимирязева, 16

Nadezhda V. Nemchinova – Clinical Research Assistant Researcher at the Laboratory of Personalized Medicine

Timiryazeva str. 16, Irkutsk 664003

nemchinova.nad@gmail.comhttps://orcid.org/0000-0003-2912-9118ПлотниковаЮ. К.PlotnikovaYu. K.

Плотникова Юлия Кимовна – главный врач

664035, г. Иркутск, ул. Cпартаковская, 11

Yulia K. Plotnikova – Director

Spartakovskaya str. 11, Irkutsk 664035

aids@aids38.ruhttps://orcid.org/0000-0003-3354-2992КолесниковаЛ. И.KolesnikovaL. I.

Колесникова Любовь Ильинична – доктор медицинских наук, профессор, академик РАН, Заслуженный деятель науки РФ, научный руководитель

664003, г. Иркутск, ул. Тимирязева, 16

Lyubov I. Kolesnikova – Dr. Sc. (Med.), Professor, Member of the RAS, Honored Scientist of the Russian Federation, Academic Advisor

Timiryazeva str. 16, Irkutsk 664003

iphr@sbamsr.irk.ruhttps://orcid.org/0000-0002-0117-2563РычковаЛ. В.RychkovaL. V.

Рычкова Любовь Владимировна – доктор медицинских наук, профессор, член-корреспондент РАН, директор

664003, г. Иркутск, ул. Тимирязева, 16

Lyubov V. Rychkova – Dr. Sc. (Med.), Professor, Corresponding Member of the RAS, Director

Timiryazeva str. 16, Irkutsk 664003

iphr@sbamsr.irk.ruФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»Scientific Centre for Family Health and Human Reproduction ProblemsФГБНУ «Научный центр проблем здоровья семьи и репродукции человека»; ГБУЗ «Иркутский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»Scientific Centre for Family Health and Human Reproduction Problems4; Irkutsk Regional Center for the Prevention and Control of AIDS and Infectious DiseasesГБУЗ «Иркутский областной центр по профилактике и борьбе со СПИД и инфекционными заболеваниями»Irkutsk Regional Center for the Prevention and Control of AIDS and Infectious Diseases20242207202493102110Copyright © Самбялова А.Ю., Баирова Т.А., Бельских А.В., Манаенкова Т.Л., Беляева Е.В., Ершова О.А., Немчинова Н.В., Плотникова Ю.К., Колесникова Л.И., Рычкова Л.В., 20242024Самбялова А.Ю., Баирова Т.А., Бельских А.В., Манаенкова Т.Л., Беляева Е.В., Ершова О.А., Немчинова Н.В., Плотникова Ю.К., Колесникова Л.И., Рычкова Л.В.Sambyalova A.Y., Bairova T.A., Belskikh A.V., Manaenkova T.L., Belyaeva E.V., Ershova O.A., Nemchinova N.V., Plotnikova Y.K., Kolesnikova L.I., Rychkova L.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.actabiomedica.ru/jour/article/view/4820

Терапевтический лекарственный мониторинг – практика измерения концентрации лекарственного препарата в биологических жидкостях пациента для оценки эффективности и безопасности лекарственной терапии. Результаты определения уровня лекарственного препарата в биологических жидкостях также могут указывать на несоблюдение режима лечения и низкую приверженность к терапии.Цель исследования. Сравнить концентрации некоторых антиретровирусных препаратов (лопинавир, ритонавир, ламивудин, абакавир, зидовудин) у детей, живущих с ВИЧ-инфекцией, в разных возрастных группах. Методы. Обследовано 184 ребёнка с перинатальной ВИЧ-инфекцией, которым проведён терапевтический лекарственный мониторинг нуклеозидных ингибиторов обратной транскриптазы (НИОТ) (ламивудин, абакавир, зидовудин) и ингибиторов протеазы (лопинавир, ритонавир). Дети разделены на 4 возрастные группы. В первую группу включены дети 1–2 лет (n = 7); во вторую – дети 3–5 лет (n = 14); в третью – дети 6–11 лет (n = 78); в четвёртую – дети 12–17 лет (n = 85). Концентрацию антиретровирусных препаратов в плазме крови определяли методом высокоэффективной жидкостной хроматографии с масс-селективной детекцией.Результаты. Самая низкая концентрация лопинавира выявлена у детей 12–17 лет (3782 [2117–5046] нг/мл), которая статистически значимо отличалась от аналогичного показателя детей 6–11 лет (5614 [3521–7264] нг/ мл; p = 0.011). Для других антиретровирусных препаратов не выявлено статистически значимых различий концентраций в плазме крови у детей разных возрастных групп.Заключение. Самые низкие концентрации лопинавира детектируются у детей старше 11 лет. Для других изучаемых антиретровирусных препаратов данной закономерности не выявлено.

Therapeutic drug monitoring is the practice of measuring the concentration of a drug in patient’s biological fluids to assess the effectiveness and safety of drug therapy. The results of determining the drug level in biological fluids can also indicate noncompliance of therapy regimen and low adherence to therapy.The aim. To compare the concentrations of some antiretroviral drugs (lopinavir, ritonavir, lamivudine, abacavir, zidovudine) in children living with HIV infection of different age groups.Methods. We examined 184 children with perinatal HIV infection who underwent therapeutic drug monitoring of nucleoside reverse transcriptase inhibitors (lamivudine, abacavir, zidovudine) and protease inhibitors (lopinavir, ritonavir). Children were divided into four age groups. Group 1 included children 1–2 years old (n = 7); group 2 – children 3–5 years old (n = 14); group 3 – children 6–11 years old (n = 78); group 4 – children 12–17 years old (n = 85). The concentration of antiretroviral drugs in blood plasma was determined using high-performance liquid chromatography with mass selective detection.Results. The lowest lopinavir concentration was found in children 12–17 years old (3782 [2117–5046] ng/ml), which was statistically significantly different from the similar values in children 6–11 years old (5614 [3521–7264] ng/ml; p = 0.011). For other antiretroviral drugs, no statistically significant differences in blood plasma concentrations were found in children of different age groups.Conclusion. The lowest lopinavir concentrations are detected in children older than 11 years. For the other studied antiretroviral drugs, this pattern was not revealed

антиретровирусная терапияВИЧ-инфекциятерапевтический лекарственный мониторингдети и подросткиприверженностьantiretroviral therapyHIV infectiontherapeutic drug monitoringchildren and adolescentsadherenceReferencesUNAIDS. URL: https://www.unaids.org/ru/resources/factsheet [date of access: 15.03.2024].UNAIDS. URL: https://www.unaids.org/ru/resources/factsheet date of access: 15.03.2024.Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017.Guidelines for managing advanced HIV disease and rapid initiation of antiretroviral therapy. Geneva: World Health Organization; 2017.Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, et al. Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV. Ther Drug Monit. 2019; 41(4): 431-443. doi: 10.1097/FTD.0000000000000637Waalewijn H, Turkova A, Rakhmanina N, Cressey TR, Penazzato M, Colbers A, et al. Optimizing pediatric dosing recommendations and treatment management of antiretroviral drugs using therapeutic drug monitoring data in children living with HIV. Ther Drug Monit. 2019; 41(4): 431-443. doi: 10.1097/FTD.0000000000000637Petrova A, Vaniarkina A, Plotnikova J, Rychkova L, Moskaleva E. Impact of combined antiretroviral prophylaxis on health outcomes in HIV exposed neonates. Arch Dis Child. 2019; 104(Suppl 3): A4. doi: 10.1136/archdischild-2019-epa.9Petrova A, Vaniarkina A, Plotnikova J, Rychkova L, Moskaleva E. Impact of combined antiretroviral prophylaxis on health outcomes in HIV exposed neonates. Arch Dis Child. 2019; 104(Suppl 3): A4. doi: 10.1136/archdischild-2019-epa.9Shugaeva S, Petrova A, Vaniarkina A, Rychkova L. Health problems in neonates with perinatal HIV exposure. Arch Dis Child. 2019; 104(Suppl 3): A143. doi: 10.1136/archdischild-2019-epa.329Shugaeva S, Petrova A, Vaniarkina A, Rychkova L. Health problems in neonates with perinatal HIV exposure. Arch Dis Child. 2019; 104(Suppl 3): A143. doi: 10.1136/archdischild-2019-epa.329Рашидова М.А., Шолохов Л.Ф., Марянян А.Ю., Колесникова Л.И. ВИЧ и беременность: реалии XXI века. Сибирский научный медицинский журнал. 2022; 42(2): 10-17. doi: 10.18699/SSMJ20220202Rashidova MA, Sholokhov LF, Marianian AYu, Kolesnikova LI. HIV and pregnancy: Realities of XXI century. Siberian Scientific Medical Journal. 2022; 42(2): 10-17. (In Russ.). doi: 10.18699/SSMJ20220202Самбялова А.Ю., Баирова Т.А., Манаенкова Т.Л., Бельских А.В., Плотникова Ю.К., Рычкова Л.В. Вирусологическая неэффективность антиретровирусной терапии и связанные с ней социальные и клинические факторы у детей и подростков, живущих с ВИЧ-инфекцией. Журнал инфектологии. 2022; 14(5): 51-59. doi: 10.22625/2072-6732-2022-14-5-51-59Sambyalova AYu, Bairova TA, Manaenkova TL, Belskikh AV, Plotnikova YuK, Rychkova LV. Virological failure of antiretroviral therapy and associated social and clinical factors in children and adolescents living with HIV. Journal Infectology. 2022; 14(5): 51-59. (In Russ.). doi: 10.22625/2072-6732-2022-14-5-51-59Vreeman RC, Scanlon ML, Tu W, Slaven JE, McAteer CI, Kerr SJ, et al. Validation of a self-report adherence measurement tool among a multinational cohort of children living with HIV in Kenya, South Africa and Thailand. J Int AIDS Soc. 2019; 22(5): e25304. doi: 10.1002/jia2.25304Vreeman RC, Scanlon ML, Tu W, Slaven JE, McAteer CI, Kerr SJ, et al. Validation of a self-report adherence measurement tool among a multinational cohort of children living with HIV in Kenya, South Africa and Thailand. J Int AIDS Soc. 2019; 22(5): e25304. doi: 10.1002/jia2.25304Самбялова А.Ю., Баирова Т.А., Манаенкова Т.Л., Бельских А.В., Беляева Е.В., Ершова О.А., и др. Некоторые фармакогенетические аспекты гена ABCB1 в вариативности концентрации лопинавира/ритонавира у детей с ВИЧ-инфекцией: пилотное исследование. Acta biomedica scientifica. 2022; 7(5-1): 53-61. doi: 10.29413/ABS.2022-7.5-1.7Sambyalova AYu, Bairova TA, Manaenkova TL, Belskikh AV, Belyaeva EV, Ershova OA, et al. Some pharmacogenetic aspects of the ABCB1 gene in lopinavir/ritonavir concentration variability in children with HIV infection: A pilot study. Acta biomedica scientifica. 2022; 7(5-1): 53-61. (In Russ.). doi: 10.29413/ABS.2022-7.5-1.7Национальная ассоциация специалистов по профилактике, диагностике и лечению ВИЧ-инфекции. ВИЧ-инфекция у детей: клинические рекомендации. М.; 2020.National Association of Specialists in Prevention, Diagnostics and Treatment of HIV Infection. HIV infection in children: Clinical recommendations. Moscow; 2020. (In Russ.)Акулова М.В. Методы оценки, контроля и повышения приверженности антиретровирусной терапии. Методическое пособие для медицинских специалистов по вопросам приверженности пациентов с ВИЧ-инфекцией АРВ-терапии. 2016.Akulova MV. Methods of assessment, control and improvement of adherence to antiretroviral therapy. Guidelines for medical specialists on the adherence of patients with HIV infection to antiretroviral therapy. 2016. (In Russ.).von Bibra M, Rosenkranz B, Pretorius E, Rabie H, Edson C, Lenker U, et al. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice? Paediatr Int Child Health. 2014; 34(2): 138-141. doi: 10.1179/2 046905513Y.0000000090von Bibra M, Rosenkranz B, Pretorius E, Rabie H, Edson C, Lenker U, et al. Are lopinavir and efavirenz serum concentrations in HIV-infected children in the therapeutic range in clinical practice? Paediatr Int Child Health. 2014; 34(2): 138-141. doi: 10.1179/2 046905513Y.0000000090Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4): 399-406. doi: 10.3851/IMP2749Moholisa RR, Schomaker M, Kuhn L, Meredith S, Wiesner L, Coovadia A, et al. Plasma lopinavir concentrations predict virological failure in a cohort of South African children initiating a protease-inhibitor-based regimen. Antivir Ther. 2014; 19(4): 399-406. doi: 10.3851/IMP2749Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother. 2009; 53(10): 4407-4413. doi: 10.1128/AAC.01594-08Hirt D, Urien S, Olivier M, Peyrière H, Nacro B, Diagbouga S, et al. Is the recommended dose of efavirenz optimal in young West African human immunodeficiency virus-infected children? Antimicrob Agents Chemother. 2009; 53(10): 4407-4413. doi: 10.1128/AAC.01594-08Rakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010; 32(3): 273-281. doi: 10.1097/FTD.0b013e3181dca14bRakhmanina NY, van den Anker JN, Soldin SJ, van Schaik RH, Mordwinkin N, Neely MN. Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents? Ther Drug Monit. 2010; 32(3): 273-281. doi: 10.1097/FTD.0b013e3181dca14bvan Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002; 21(8): 743-747. doi: 10.1097/00006454-200208000-00009van Rossum AM, Bergshoeff AS, Fraaij PL, Hugen PW, Hartwig NG, Geelen SP, et al. Therapeutic drug monitoring of indinavir and nelfinavir to assess adherence to therapy in human immunodeficiency virus-infected children. Pediatr Infect Dis J. 2002; 21(8): 743-747. doi: 10.1097/00006454-200208000-00009van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002; 2(2): 93-102. doi: 10.1016/s1473-3099(02)00183-4van Rossum AM, Fraaij PL, de Groot R. Efficacy of highly active antiretroviral therapy in HIV-1 infected children. Lancet Infect Dis. 2002; 2(2): 93-102. doi: 10.1016/s1473-3099(02)00183-4Engelbrecht AE, Wiesner L, Norman J, Rabie H, Decloedt EH. Pediatric antiretroviral therapeutic drug monitoring: A five and a half year experience from a South African tertiary hospital. J Trop Pediatr. 2020; 66(4): 385-394. doi: 10.1093/tropej/fmz077Engelbrecht AE, Wiesner L, Norman J, Rabie H, Decloedt EH. Pediatric antiretroviral therapeutic drug monitoring: A five and a half year experience from a South African tertiary hospital. J Trop Pediatr. 2020; 66(4): 385-394. doi: 10.1093/tropej/fmz077HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV – A Working Group of the NIH Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in pediatric HIV infection. URL: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new [date of access: 05.03.2024].HHS Panel on Antiretroviral Therapy and Medical Management of Children Living with HIV – A Working Group of the NIH Office of AIDS Research Advisory Council (OARAC). Guidelines for the use of antiretroviral agents in pediatric HIV infection. URL: https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/whats-new date of access: 05.03.2024.FDA. FDA drug safety communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. URL: https://www.fda.gov/Drugs/DrugSafety/ucm246002.htm [date of access: 01.03.2024].FDA. FDA drug safety communication: Serious health problems seen in premature babies given Kaletra (lopinavir/ritonavir) oral solution. URL: https://www.fda.gov/Drugs/DrugSafety/ucm246002.htm date of access: 01.03.2024.Barlow-Mosha L, Angelidou K, Lindsey J, Archary M, Cotton M, Dittmer S, et al. Nevirapine-versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: Long-term follow-up of the IMPAACT P1060 randomized trial. Clin Infect Dis. 2016; 63(8): 1113-1121. doi: 10.1093/cid/ciw488Barlow-Mosha L, Angelidou K, Lindsey J, Archary M, Cotton M, Dittmer S, et al. Nevirapine-versus lopinavir/ritonavir-based antiretroviral therapy in HIV-infected infants and young children: Long-term follow-up of the IMPAACT P1060 randomized trial. Clin Infect Dis. 2016; 63(8): 1113-1121. doi: 10.1093/cid/ciw488Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009; 53(6): 2532-2538. doi: 10.1128/AAC.01374-08Rakhmanina N, van den Anker J, Baghdassarian A, Soldin S, Williams K, Neely MN. Population pharmacokinetics of lopinavir predict suboptimal therapeutic concentrations in treatment-experienced human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 2009; 53(6): 2532-2538. doi: 10.1128/AAC.01374-08Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, et al. Population pharmacokinetics of lopinavir/ritonavir: Changes across formulations and human development from infancy through adulthood. J Clin Pharmacol. 2018; 58(12): 1604-1617. doi: 10.1002/jcph.1293Yang J, Nikanjam M, Best BM, Pinto J, Chadwick EG, Daar ES, et al. Population pharmacokinetics of lopinavir/ritonavir: Changes across formulations and human development from infancy through adulthood. J Clin Pharmacol. 2018; 58(12): 1604-1617. doi: 10.1002/jcph.1293Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000; 14(14): 2137-2144. doi: 10.1097/00002030-200009290-00010Fletcher CV, Kawle SP, Kakuda TN, Anderson PL, Weller D, Bushman LR, et al. Zidovudine triphosphate and lamivudine triphosphate concentration-response relationships in HIV-infected persons. AIDS. 2000; 14(14): 2137-2144. doi: 10.1097/00002030-200009290-00010Kinai E, Kato S, Hosokawa S, Sadatsuki M, Gatanaga H, Kikuchi Y, et al. High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. J Acquir Immune Defic Syndr. 2016; 72(3): 246-253. doi: 10.1097/QAI.0000000000000950Kinai E, Kato S, Hosokawa S, Sadatsuki M, Gatanaga H, Kikuchi Y, et al. High plasma concentrations of zidovudine (AZT) do not parallel intracellular concentrations of AZT-triphosphates in infants during prevention of mother-to-child HIV-1 transmission. J Acquir Immune Defic Syndr. 2016; 72(3): 246-253. doi: 10.1097/QAI.0000000000000950

The authors declare that there are no conflicts of interest present.